What’s the sensitivity required for optimal molecular testing in NSCLC? Dr. Erwan Pencreach presents the results from a retrospective technical analysis, after a year of routine NSCLC molecular testing with the MassARRAY System, from a biological/clinical and economical point of view.
- Understand the role of driver mutations and actionable targets, like T790M, L858R and exon 19 deletions in EGFR.
- Supplement clinical analyses of routine NSCLC molecular testing with economic considerations.
- Evaluate the MassARRAY technology for melanoma, lung, breast and colon cancers in comparison with NGS.
Erwan Pencreach, PharmD, PhD
Department of Molecular Oncology, Strasbourg University Hospital, France
Recorded on July 28, 2020
Learn more about our liquid biopsy and tumor profiling solutions.